Accorto Visits 2FIRSTS: Charting Path for High-Quality Development of E-Cig Enterprises in US

2Firsts Events by 2FIRSTS, edited by Sophia Lv
Aug.19.2024
Accorto Visits 2FIRSTS: Charting Path for High-Quality Development of E-Cig Enterprises in US
Accorto CEO Tom Beaudet and CSO Dr. Vince Angelico visit 2FIRSTS HQ for in-depth discussion on US e-cigarette industry.

On August 19, Tom Beaudet, CEO of the U.S. compliance company Accorto, and Dr. Vince Angelico, CSO (Chief Scientific Officer), visited the headquarters of 2FIRSTS to have a detailed discussion with Alan Zhao, co-founder and CEO of 2FIRSTS. Both sides explored the high-quality development of the e-cigarette industry in the American market.

 

Accorto Visits 2FIRSTS: Charting Path for High-Quality Development of E-Cig Enterprises in US
Tom (third from the right), Vincent (fourth from the right), Alan Zhao (second from the right), and 2FIRSTS staff members posing for a photo. | Image source: 2FIRSTS

 

During the meeting, Alan Zhao warmly welcomed the arrival of the Accorto delegation and expressed appreciation for their professional insights in the field of PMTA compliance. Alan Zhao stated that with the U.S. Food and Drug Administration (FDA) continuously strengthening its regulation and enforcement of the e-cigarette market, compliance in the e-cigarette industry has become a crucial issue that companies cannot afford to overlook. In the face of market changes, companies must pay close attention to compliance services in order to ensure their sustainable and steady development.

 

Accorto Visits 2FIRSTS: Charting Path for High-Quality Development of E-Cig Enterprises in US
2024 Global New Tobacco Regulations Report" produced by 2FIRSTS|Image source: 2FIRSTS

 

In order to deepen mutual understanding and cooperation, Alan Zhao on behalf of 2FIRSTS presented Tom with the "2024 Global New Tobacco Regulation Report" (English version) produced by 2FIRSTS. The report provides a comprehensive analysis of the current global regulation of novel tobacco products and their development trends, offering valuable insights and guidance to the industry.

 

Tom highly praised 2FIRSTS' professionalism and contribution to the industry's development, and stated that he looks forward to deeper collaboration with 2FIRSTS in the e-cigarette compliance field in the future. Accorto, as a leading provider of PMTA compliance services, has been dedicated to assisting e-cigarette companies in FDA reviews to ensure products can legally enter the US market.

 

This exchange not only deepened mutual understanding between both parties, but also laid a solid foundation for future cooperation. 2FIRSTS and Accorto have both expressed their commitment to working together to promote the healthy and orderly development of the e-cigarette industry, providing global consumers with safer and more compliant e-cigarette products.

 

As a key media and research institution in the e-cigarette industry, 2FIRSTS will continue to leverage its influence within the industry to promote information exchange and knowledge sharing. We will work with partners like Accorto to contribute to the high-quality development of the e-cigarette industry.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

2Firsts Hosts China Market Forum at InterTabac as Global Industry Attention to China’s Tobacco Sector Deepens
2Firsts Hosts China Market Forum at InterTabac as Global Industry Attention to China’s Tobacco Sector Deepens
On September 16, 2Firsts hosted a China-focused industry forum during InterTabac in Dortmund, bringing together more than 30 participants from North America, Europe, India, South Korea and other markets. The session covered traditional tobacco, next-generation products, exports, technology, regulation and supply chains, while examining how China’s tobacco sector operates, where its transformation may be heading, and why its growing role matters increasingly to companies across the global tobacco and nicotine industry.
Sep.21
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
At the 2026 New Approaches Summit in New York, FDA Center for Tobacco Products Director Bret Koplow said the PMTA pathway is “predicated on tobacco harm reduction.” He outlined four CTP priorities: youth prevention, helping adults quit or switch to lower-risk products, improving relative-risk communication, and reducing unauthorized products. Koplow also addressed flavored e-cigarettes, public risk perceptions, industry credibility and efforts to make PMTA reviews more efficient and predictable.
Sep.26
Couche-Tard Posts Double-Digit U.S. Same-Store Growth in Other Nicotine Products, Led by Pouches
Couche-Tard Posts Double-Digit U.S. Same-Store Growth in Other Nicotine Products, Led by Pouches
Alimentation Couche-Tard said U.S. same-store sales in its “other nicotine products” category grew at a double-digit rate in the first quarter of fiscal 2027, led by nicotine pouches, while overall U.S. same-store merchandise revenues increased 1.7%. The company also said its Canadian nicotine business continued to face regulatory pressure and illicit-market headwinds. The U.S. performance coincides with Couche-Tard's participation in efforts to reopen Canadian convenience-store access to authorized nicotine pouches, though the company has not established a direct causal link between the two.
Sep.14
FRE and ALP Push Modern Oral to 48% of Q2 Sales as Turning Point Brands Changes CEO and Lowers Profit-Guidance Ceiling
FRE and ALP Push Modern Oral to 48% of Q2 Sales as Turning Point Brands Changes CEO and Lowers Profit-Guidance Ceiling
Turning Point Brands said Executive Chairman David E. Glazek will become CEO on October 1, replacing Graham Purdy, who is stepping down for personal reasons. The company narrowed its 2026 adjusted EBITDA outlook to $70 million-$80 million from $70 million-$90 million while maintaining Modern Oral gross sales guidance of $330 million-$350 million and net sales guidance of $260 million-$270 million. In the second quarter, Modern Oral net sales rose 128% to $68.4 million and accounted for 48% of company-wide net sales. Adjusted EBITDA fell 50% year over year. TPB shares closed about 10% lower on September 21.
Market
Sep.22 by 2Firsts Perspectives
Product | PIXL Adds 6ml PIXL 5K in UK Alongside 12ml PIXL 8000 as Vape Duty Takes Effect
Product | PIXL Adds 6ml PIXL 5K in UK Alongside 12ml PIXL 8000 as Vape Duty Takes Effect
Vaping brand PIXL has introduced the PIXL 5K reusable prefilled pod device in the UK, featuring a 2ml prefilled pod and a 4ml refill container with a combined e-liquid capacity of 6ml. The device uses 20mg/ml nicotine salt e-liquid and is advertised to deliver up to approximately 5,000 puffs. Available through UK retailers by August 2026, the PIXL 5K sits alongside the existing 12ml PIXL 8000. The UK's Vaping Products Duty took effect on October 1 at £0.22 per millilitre, producing theoretical duty amounts of £1.32 and £2.64 for the two products' respective full refill sets.
product
Oct.10
From Product Innovation to Integrated Solutions: NEXTECH Expands Its Global Heated Tobacco Solutions
From Product Innovation to Integrated Solutions: NEXTECH Expands Its Global Heated Tobacco Solutions
NEXTECH launched its NEXE Pro circumferential-heating tobacco stick globally at InterTabac 2026, as the company expands from product innovation into broader heated tobacco solutions. Amid intensifying competition across global HTP markets, NEXTECH is strengthening its R&D, manufacturing and pre-launch support capabilities to serve different types of business customers.
Industry Insight
Sep.15